News & Updates
Filter by Specialty:
6-month secukinumab use improves outcomes in psoriatic arthritis
Real-world patients with psoriatic arthritis (PsA) who received and remained on secukinumab treatment for 6 months has attained minimal disease activity (MDA) and shown improvements in clinical manifestations, patient-reported outcomes, and work productivity at follow-up, reveals a study. The results are consistent with findings from clinical trials.
6-month secukinumab use improves outcomes in psoriatic arthritis
21 Jul 2022Which factors predict hospitalization for acute gout?
Several factors, including older age, overnight emergency department (ED) arrival time, higher serum urate (SU), higher C-reactive protein (CRP), and higher total white cell count at presentation, predict hospitalization for acute gout, according to a study.
Which factors predict hospitalization for acute gout?
21 Jul 2022Pre-eclampsia ups risk of nonsyndromic orofacial clefts
Only pre-eclampsia, among other hypertensive disorders of pregnancy, contributes to a higher risk of nonsyndromic orofacial clefts (NSOFCs) and its subtypes, a study has found.
Pre-eclampsia ups risk of nonsyndromic orofacial clefts
21 Jul 2022Tirzepatide beneficial for shedding pounds in obese adults
Once-weekly treatment with tirzepatide in adults with obesity appears to yield substantial and sustained reductions in body weight, according to the phase III SURMOUNT-1 trial.
Tirzepatide beneficial for shedding pounds in obese adults
21 Jul 2022Women hospitalized with COVID-19 suffer from menstrual changes, worse mental health
COVID-19 appears to alter the menstrual cycle and impair mental health in women hospitalized for the disease, a recent study has found.
Women hospitalized with COVID-19 suffer from menstrual changes, worse mental health
21 Jul 2022Real-world studies demonstrate TAF efficacy and safety in chronic hep B
Treatment with tenofovir alafenamide (TAF) results in similar virological response compared with tenofovir disoproxil fumarate (TDF) in treatment-naïve patients with chronic hepatitis B (CHB), according to a real-world study from Korea presented at ILC 2022.